Acquisition of serum antibodies against filamentous hemagglutinin and pertactin unrelated to Bordetella pertussis infection

Clinical Microbiology and Infection

Volumn 5, Issue 11, 1999, Pages 709-712

  Carlsson, Rose Marie ^a   Claesson, Bo A ^a   Lagergård, Teresa ^b   Trollfors, Birger ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; PERTACTIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; HUMAN; IMMUNOGENICITY; INFANT; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL;

BORDETELLA PERTUSSIS;

EID: 0032749236     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00520.x     Document Type: Article

References (19)

1. Granström G, Wretlind B, Salenstedt C-R, Granström M. Evaluation of serologic assays for diagnosis of whooping cough. J Clin Microbiol 1988; 9: 1818-23.
2. Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 1995; 27: 273-7.
3. StorsaeterJ, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907-16.
4. Charles IG, Li LJ, Strugnell R, et al. Repeat sequence motifs constitute the immunodominant regions of the P.69 protein, pertactin, from Bordetella pertussis: comparison with repeat sequences from Bordetella parapertussis and Bordetella bronchiseptica. In Manclark CR, ed. Proceedings of the Sixth International Symposium on Pertussis. Department of Health and Human Services, DHHS Publication (FDA) 90-1164. Bethesda, MD: United States Public Health Service, 1990: 136-40.
5. Irons LI, Ashworth LAE, Wilton-Smith P. Heterogeneity of the filamentous hemagglutinin of Bordetella pertussis studied with monoclonal antibodies. J Gen Microbiol 1983; 129: 2769-78.
6. Barenkamp SJ, Leininger E. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis. Infect Immun 1992; 60: 1302-13.
7. Shapiro ED, Ward JI. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. Epidemiol Rev 1991; 13: 113-42.
8. Isacson J, Trollfors B, Taranger J, Lagergård T. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis. Pediatr Infect Dis J 1995; 14: 517-21.
9. Carlsson R-M, Claesson BA, Iwarson S, Lagergård T, Käyhty H. Antibodies against Haemophilus influenzae type b and tetanus in infants after subcutaneous vaccination with PRP-T/diphtheria, or PRP-OMP/diphtheria-tetanus vaccines. Pediatr Infect Dis J 1994; 13: 27-33.
10. Carlsson R-M, Claesson BA, Lagergård T, Käyhty H. Serum antibodies against Haemophilus influenzae type b and tetanus at 2.5 years of age: a follow-up of two different regimens of infant vaccination. Scand J Infect Dis 1996; 28: 519-23.
11. Claesson BA, Schneerson R, Lagergård T, et al. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. Pediatr Infect Dis J 1991; 10: 560-4.
12. Claesson BA, Trollfors B, Anderson PW, et al. Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 1996; 15: 170-2.
13. Taranger J, Trollfors B, Lagergård T. Clinical trials of a monocomponent pertussis toxoid vaccine (NICHD-Ptxd) - a technical report. The Göteborg Pertussis Vaccine Study, Göteborg University, Göteborg, Sweden. Graphic Systems, 1995.
14. Trollfors B, Zackrisson G, Taranger J, Lagergård T. Serum antibodies against a 69-kilodalton outer-membrane protein, pertactin, from Bordetella pertussis in nonvaccinated children with and without a history of clinical pertussis. J Pediatr 1992; 120: 924-6.
15. Reizenstein E, Hallander H-O, Blackwelder WC, Kühn I, Ljungman M, Möllby R. Comparison of five calculation modes tor antibody ELISA procedures using pertussis serology as a model. J Immunol Meth 1995; 183: 279-90.
16. Trollfors B, Taranger J, Lagergård T, et al. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. Clin Infect Dis 1999; 28: 552-9.
17. Zachrisson G, Taranger J, Trollfors B. History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr 1990; 116: 190-4.
18. Mark A, Granström M. Cumulative incidence of pertussis in an unvaccinated preschool cohort based on notifications, interview and serology. Eur J Epidemiol 1991; 7: 121-6.
19. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333: 1045-50.